Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid business. The biotech company said it expects 10 new product approvals through 2027. But Moderna said it will also pause work on some products in its pipeline and scrap others, as it aims to "pace ourselves" in new research and development spending. The company aims to trim R&D spending to a range of $3.6 billion to $3.8 ...

NEW YORK, Sept. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=101868&from=4 CLASS PERIOD: January 18, 2023 to June 2 ...

Building on successful pre-clinical in vivo CAR-M data in oncology, the companies will develop in vivo CAR-M for autoimmune diseases Moderna nominated two autoimmune disease targets under the collaboration Carisma is eligible to receive milestones and royalty payments PHILADELPHIA, Sept. 10, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced th ...

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

Moderna, Inc. (MRNA) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) has rendered a positive opinion recommending marketing authorization for its updated formulation of the mRNA-based COVID-19 vaccine, Spikevax, targeting the variant JN.1. The CHMP recommended marketing approval to Spikevax, targeting the variant JN.1, for active immunization to prevent COVID-19 in individuals aged six months and above. Pending a decision from the European Co ...

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

NEW YORK , Sept. 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=100107&from=4 CLASS PERIOD: January 18, 2023 to June 2 ...

SAN DIEGO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Moderna, Inc. (NASDAQ: MRNA) securities between January 18, 2023 and June 25, 2024. Moderna is a biotechnology company that discovers, develops, and commercializes messenger RNA ("mRNA") therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular dis ...

NEW YORK, Sept. 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

NEW YORK, Aug. 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=98706&from=4 CLASS PERIOD: January 18, 2023 to June 25, ...